Alamar Biosciences closed at $27.39 on Nov 4, down 9.36%, 28.2% below its highest close since Sep 11. Volume of 1.5M shares was 1.91× its 20-day average (above normal).
Split-adjusted performance: -15.1% over one month.
In the quarter ended Jun 30, 2026, revenue was $29.43M, with a net margin of -44.9%.
Short interest was 2.7M shares at the Oct 15 settlement, down 4.8% from the prior report (7.6% of float, 3.1 days to cover).
No reported quarters with price history yet.
Percentile among 22 companies (100 = best)
Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ALMRAlamar Biosciences | $27.39 | −9.36% | — | — | −44.9% | — | $1.90B | |
| PACBPacific Biosciences of California | $2.55 | +4.51% | +49.1% | −1.9% | −114.7% | — | $792.6M | Compare |
| CTKBCytek Biosciences | $5.88 | −1.34% | +19.0% | +5.6% | −25.3% | — | $764.3M | Compare |
| MASS908 Devices | $11.07 | +3.75% | +37.3% | +23.3% | −74.0% | — | $457.6M | Compare |
| TXG10x Genomics | $67.52 | +3.42% | +196.9% | −12.6% | −11.9% | — | $8.80B | Compare |
| BRKRBruker | $63.79 | +12.90% | +50.8% | +5.2% | −7.5% | — | $9.72B | Compare |
| BIO.BBio-Rad Laboratories | $379.50 | +4.22% | — | −0.1% | 57.1% | 45.6 | $10.15B | Compare |
| BIOBio-Rad Laboratories | $379.99 | +1.35% | +46.7% | −0.1% | 57.1% | 45.7 | $10.16B | Compare |
| AVTRAvantor | $15.65 | +0.38% | +85.6% | +4.6% | 12.0% | 31.4 | $10.60B | Compare |
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
